

Glaukos Announces the Release of its 2020 Sustainability Report

4/27/2021

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2020 Sustainability Report. The report highlights the company's continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company's website [here](#).

"I am proud to issue our second annual Sustainability Report that significantly builds upon the inaugural Sustainability Report we issued last year as we strive to continue to grow and enhance our ESG policies and programs," said Thomas Burns, Glaukos president and chief executive officer. "Over the course of 2020, we invested significant time and resources into better understanding what drives sustainability at Glaukos, establishing meaningful goals to propel us forward on ESG matters and examining how best to present our progress to our stakeholders. Our commitment to continual improvement as responsible corporate citizens is unwavering and we hope that our 2020 Sustainability Report reflects that dedication."

Over the course of 2020, Glaukos undertook several actions to further improve its ESG efforts and reporting framework. First, Glaukos included ESG as a Compensation, Nominating and Governance Committee responsibility included in that Committee's charter to allow for direct Board oversight of ESG matters. In addition, Glaukos created a new Sustainability Council comprised of cross-functional senior subject matter experts across various departments in the organization to drive execution and implementation of the sustainability program. Finally, Glaukos completed a thorough process to prioritize ESG topics that it believes to be most impactful to the company's business, incorporating input from multiple internal and external sources and stakeholders. Based upon

these prioritized topics, Glaukos established and published its sustainability goals for the near future.

Glaukos' 2020 Sustainability Report can be found on the company's website [here](#).

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Forward-Looking Statements

All statements other than statements of historical facts included in this report that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current business aspirations and expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability targets identified in the sustainability report. Risks, uncertainties and factors related to Glaukos and our business are described in detail under the caption "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on March 1, 2021. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. Readers are cautioned not to place undue reliance on any estimate, aspirational targets or forward-looking statement contained herein, which speak only as of the date made. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210427005456/en/): <https://www.businesswire.com/news/home/20210427005456/en/>

Investor Contact:

Chris Lewis

Sr. Director, Investor Relations & Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation